Arun Kumar Arumugam Raajasekar
Hematology & Oncology · Yuma, AZNPI 1801143722
Payments from drug & device makers
Across 25 payments — averaging $14,648 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$140K
- Novartis$117K
- AstraZeneca$78K
- Janssen Research & Development, LLC$31K
- Tersera Therapeutics LLC$942
- Johnson & Johnson$62
- plus $65 from 3 others
What the payments were for
- Consulting fees$94283%
- Food & beverage$837%
- Education$11510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 3 | $140,091 |
| Novartis | 5 | $116,918 |
| AstraZeneca | 4 | $77,521 |
| Janssen Research & Development, LLC | 7 | $30,597 |
| Tersera Therapeutics LLC | 2 | $942 |
| Johnson & Johnson | 1 | $62 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Sanofi | 1 | $21 |
| Gilead | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MARGENZA$942
How this compares
$366,195 in reported general payments places this provider in the 70th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 130 | $1,768,259 |
| CabometyxCabozantinib S-Malate | 46 | $1,101,174 |
| PomalystPomalidomide | 15 | $357,020 |
| Abiraterone Acetate | 147 | $269,289 |
| NubeqaDarolutamide | 17 | $230,872 |
| InlytaAxitinib | 11 | $213,626 |
| EliquisApixaban | 26 | $15,797 |
| Enoxaparin Sodium | 11 | $2,457 |
| Prochlorperazine Maleate | 133 | $1,793 |
| Ondansetron Hcl | 119 | $1,735 |
| Prednisone | 155 | $1,116 |
| Dexamethasone | 61 | $1,102 |
| Potassium Chloride | 21 | $946 |
| Hydroxyurea | 28 | $772 |
| Triamcinolone Acetonide | 14 | $647 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Yuma
- Abhinav ChandraYuma$1.2M
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Jiaxin NiuGilbert$10.7M
- Sudhir MandaTucson$10M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Mikhail ShtivelbandChandler$9.1M
- Daniel AhnScottsdale$9.1M
- Javier MunozPhoenix$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.